PharmaCyte Biotech, Inc. - 04 Sep 2025 Form 4 Insider Report for Q/C TECHNOLOGIES, INC. (TNFA)

Role: 10%+ Owner
Signature: PharmaCyte Biotech, Inc. By: /s/ Carlos A. Trujillo, Chief Financial Officer
Issuer symbol: TNFA
Transactions as of: 04 Sep 2025
Net transactions value: $0
Form type: 4
Filing time: 18 Nov 2025, 16:32:29 UTC
Previous filing: 30 May 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
PharmaCyte Biotech, Inc.	10%+ Owner	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS	PharmaCyte Biotech, Inc. By: /s/ Carlos A. Trujillo, Chief Financial Officer	18 Nov 2025	0001157075

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QCLS	Series H Convertible Preferred Stock	Purchase		+889,865			889,865	04 Sep 2025	Common stock, par value $0.001 per share	889,865		Direct	F1
transaction	QCLS	Warrants	Purchase		+889,865			889,865	14 Nov 2025	Common stock, par value $0.001 per share	889,865		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.

Content

The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.